SCENESSE Drug Patent Profile

Which patents cover Scenesse, and when can generic versions of Scenesse launch?

Scenesse is a drug marketed by Clivunel Inc and is included in one NDA. There is one patent protecting this drug.

This drug has twenty-three patent family members in sixteen countries.

The generic ingredient in SCENESSE is afamelanotide. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the afamelanotide profile page.

DrugPatentWatch^® Generic Entry Outlook for Scenesse

Scenesse was eligible for patent challenges on October 8, 2023.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be October 8, 2026. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for SCENESSE

International Patents:	23
US Patents:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	23
Clinical Trials:	3
Patent Applications:	2
Drug Prices:	Drug price information for SCENESSE
What excipients (inactive ingredients) are in SCENESSE?	SCENESSE excipients list
DailyMed Link:	SCENESSE at DailyMed

See drug prices for SCENESSE

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for SCENESSE

Constraining patent/regulatory exclusivity:

INDICATED TO INCREASE PAIN FREE LIGHT EXPOSURE IN ADULT PATIENTS WITH A HISTORY OF PHOTOTOXIC REACTIONS FROM ERYTHROPOIETIC PROTOPORPHYRIA (EPP)

NDA:

210797

Dosage:

IMPLANT;SUBCUTANEOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for SCENESSE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Clinuvel, Inc.	Phase 3
Clinuvel Europe Limited	Phase 2

See all SCENESSE clinical trials

US Patents and Regulatory Information for SCENESSE

SCENESSE is protected by one US patents and one FDA Regulatory Exclusivity.

This potential generic entry date is based on INDICATED TO INCREASE PAIN FREE LIGHT EXPOSURE IN ADULT PATIENTS WITH A HISTORY OF PHOTOTOXIC REACTIONS FROM ERYTHROPOIETIC PROTOPORPHYRIA (EPP).

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Clivunel Inc	SCENESSE	afamelanotide	IMPLANT;SUBCUTANEOUS	210797-001	Oct 8, 2019		RX	Yes	Yes	8,334,265
Clivunel Inc	SCENESSE	afamelanotide	IMPLANT;SUBCUTANEOUS	210797-001	Oct 8, 2019		RX	Yes	Yes

Expired US Patents for SCENESSE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Clivunel Inc	SCENESSE	afamelanotide	IMPLANT;SUBCUTANEOUS	210797-001	Oct 8, 2019	10,076,555

EU/EMA Drug Approvals for SCENESSE

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Clinuvel Europe Limited	Scenesse	afamelanotide	EMEA/H/C/002548Prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP).	Authorised	no	no	yes	2014-12-22

International Patents for SCENESSE

See the table below for patents covering SCENESSE around the world.

Country	Patent Number	Title	Estimated Expiration
New Zealand	582130	Methods of inducing melanogenesis in a subject
European Patent Office	2865422
Luxembourg	C00062
Spain	2525476
New Zealand	575133

Supplementary Protection Certificates for SCENESSE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2865422	663	Finland
2865422	LUC00062	Luxembourg		PRODUCT NAME: AFAMELANOTIDE ET SES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES (SCENESSE); AUTHORISATION NUMBER AND DATE: EU/1/14/969 20141229
2865422	2018C/012	Belgium		PRODUCT NAME: AFAMELANOTIDE; AUTHORISATION NUMBER AND DATE: EU/1/14/969 20141229
2865422	2018/008	Ireland		PRODUCT NAME: AFAMELANOTIDE; REGISTRATION NO/DATE: EU/1/14/969 20141222
2865422	12/2018	Austria		PRODUCT NAME: AFAMELANOTID; REGISTRATION NO/DATE: EU/1/14/969 (MITTEILUNG) 20141229

SCENESSE: Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

SCENESSE (afamelanotide) is a synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH) approved for treating specific rare phototoxicity disorders. Its market trajectory is shaped by limited patient populations, complex regulatory pathways, and evolving reimbursement landscapes.

What is the approved indication for SCENESSE?

SCENESSE is approved in the United States and European Union for the treatment of erythropoietic protoporphyria (EPP) in adult patients. EPP is a rare genetic disorder characterized by severe photosensitivity, leading to debilitating pain, skin damage, and a significant reduction in quality of life upon exposure to sunlight. The drug is administered via subcutaneous implants.

What is the clinical efficacy and safety profile of SCENESSE?

Clinical trials have demonstrated that SCENESSE reduces the frequency and severity of phototoxic reactions in EPP patients. In a Phase 3 study, SCENESSE treatment resulted in a statistically significant reduction in the number of days of phototoxic reactions requiring management (e.g., confinement indoors, pain medication) compared to placebo [1]. Patients treated with SCENESSE experienced an average of 6.3 fewer days of phototoxic reactions per month [1].

The safety profile of SCENESSE is generally considered acceptable for its approved indication. Common adverse events include injection site reactions, nausea, and headache. More serious adverse events, such as skin discoloration and activation of melanocytic nevi, have been reported but are typically managed with dose adjustments or discontinuation. Long-term safety data are still being gathered, but no major unexpected safety signals have emerged in post-marketing surveillance.

What is the market size and patient population for SCENESSE?

The patient population for SCENESSE is limited due to the rarity of EPP. Estimates suggest that EPP affects approximately 1 in 75,000 to 1 in 200,000 people in Western countries [2]. This translates to a global patient pool in the low thousands. The prevalence of diagnosed and treated EPP patients is further constrained by diagnostic challenges and access to specialized care.

The market size for SCENESSE is therefore relatively small in absolute terms compared to blockbuster drugs treating more common conditions. However, its orphan drug designation and high treatment cost contribute to significant revenue generation per patient.

What is the pricing and reimbursement strategy for SCENESSE?

SCENESSE is positioned as a high-cost specialty pharmaceutical. The price reflects the significant research and development investment, the specialized manufacturing process, and the unmet medical need it addresses for a rare disease. In the U.S., a single SCENESSE implant can cost several thousand dollars, with treatment regimens requiring multiple implants annually.

Reimbursement for SCENESSE is a critical factor in market access. Given its high cost, payers, including private insurers and government programs, scrutinize its cost-effectiveness. Orphan drug status can facilitate initial market entry and encourage some payer coverage. However, ongoing efforts focus on demonstrating long-term value and improved quality of life to secure and maintain favorable reimbursement. Patient assistance programs are also often in place to help eligible patients manage out-of-pocket costs.

Who are the key competitors and what is the competitive landscape?

Currently, SCENESSE is the only approved therapy specifically for EPP in major markets. This absence of direct competition provides SCENESSE with a de facto monopoly within its approved indication. However, the competitive landscape is not static.

The development pipeline for EPP treatments includes several investigational therapies. These may include gene therapies, small molecule inhibitors, or other approaches aimed at addressing the underlying pathophysiology of the disease. Any future approval of a competing therapy could alter the market dynamics for SCENESSE.

Beyond direct EPP treatments, the standard of care for EPP patients before SCENESSE included behavioral modifications (e.g., strict sun avoidance), photoprotective clothing, and symptomatic management of pain. While not direct pharmacological competitors, these existing management strategies represent the baseline against which SCENESSE's value is assessed.

What are the key regulatory hurdles and market access challenges?

The regulatory pathway for SCENESSE, like other orphan drugs, involved rigorous clinical trials to demonstrate safety and efficacy in a small patient population. Obtaining and maintaining regulatory approval requires ongoing pharmacovigilance and adherence to post-marketing commitments.

Market access challenges are significant and multifaceted. They include:

• Payer Negotiations: Securing favorable reimbursement terms from diverse payers is an ongoing process. Payers often demand robust health economic data, including pharmacoeconomic modeling, to justify the drug's high price.
• Physician Education: Educating healthcare providers about EPP and the appropriate use of SCENESSE is crucial for patient identification and treatment initiation.
• Patient Identification: Diagnosing EPP can be challenging, leading to underdiagnosis. Efforts to improve awareness and diagnostic tools are essential for expanding the patient pool.
• Global Market Harmonization: Navigating different regulatory and reimbursement systems across various countries adds complexity to global market access strategies.

What is the financial trajectory and revenue outlook for SCENESSE?

The financial trajectory of SCENESSE is characterized by strong per-patient revenue due to its high price and orphan drug status, offset by a limited patient population. Precise revenue figures are often proprietary, but industry analysis indicates that SCENESSE has achieved significant sales since its launch, driven by the unmet need in EPP.

The revenue outlook depends on several factors:

• Patient Uptake: The rate at which eligible EPP patients are diagnosed and prescribed SCENESSE.
• Payer Coverage: The extent and breadth of reimbursement across key markets.
• Competition: The emergence of new therapies that could capture market share.
• Geographic Expansion: Successful launches and market penetration in new regions.
• Lifecycle Management: Potential for expanded indications or improved formulations, though this is less common for highly specialized orphan drugs.

The drug's financial success is predicated on maximizing value within its niche. Growth is likely to be driven by increasing physician awareness, improved diagnostic pathways, and sustained payer support rather than broad patient acquisition.

What are the intellectual property and patent considerations for SCENESSE?

The intellectual property surrounding SCENESSE is critical to its commercial viability. Patents protect the afamelanotide molecule, its synthesis, formulations, and methods of use. These patents grant market exclusivity for a defined period, allowing the manufacturer to recoup R&D investments.

Key patent considerations include:

• Expiration Dates: The timing of patent expirations is a significant factor in long-term revenue projections, as it opens the door for generic or biosimilar competition.
• Patent Litigation: Challenges to patent validity or claims of infringement can arise, creating uncertainty and potential legal costs.
• Orphan Drug Exclusivity: In addition to patent protection, regulatory agencies grant periods of market exclusivity for orphan drugs, which can provide a further layer of protection even after patent expiry. This exclusivity typically lasts for 7 years in the U.S. and 10 years in the EU for the approved indication.

Understanding the patent landscape and exclusivity periods is essential for forecasting future market share and profitability.

What is the role of patient advocacy in SCENESSE's market access?

Patient advocacy groups play a crucial role in raising awareness for rare diseases like EPP and advocating for access to treatments. For SCENESSE, these groups have been instrumental in:

• Raising Disease Awareness: Educating the public and healthcare professionals about EPP, leading to improved diagnosis rates.
• Advocating for Reimbursement: Engaging with payers and policymakers to ensure that SCENESSE is accessible to eligible patients.
• Supporting Research: Encouraging and sometimes funding research into EPP and its treatments.

The collective voice of patient advocacy can significantly influence market dynamics by driving demand, facilitating regulatory approvals, and supporting favorable reimbursement decisions.

Key Takeaways

SCENESSE's market position is defined by its status as a monotherapy for EPP, a rare phototoxicity disorder. Its financial performance is driven by a high per-patient price, a limited patient pool, and robust orphan drug protections. Key challenges include securing broad payer reimbursement and navigating the complexities of diagnosing and identifying eligible patients. The absence of direct competition currently supports its revenue generation, but the potential for future therapies necessitates ongoing market vigilance.

FAQs

1. How does SCENESSE differ from other photoprotective strategies for EPP? SCENESSE is a therapeutic agent that increases endogenous photoprotection by stimulating melanogenesis. Existing strategies are largely preventative, involving strict sun avoidance and specialized clothing.

2. What is the typical duration of SCENESSE treatment? SCENESSE is administered via subcutaneous implants typically every two months. Treatment duration is usually determined by physician assessment of patient response and disease management.

3. Are there any off-label uses or potential expanded indications for SCENESSE? While the primary approved indication is EPP, research has explored afamelanotide for other conditions related to melanin deficiency or photosensitivity, though these are not currently approved indications.

4. What are the primary drivers of SCENESSE's high cost? The high cost is attributed to the extensive R&D required for orphan drug development, specialized manufacturing processes, the small patient population necessitating a premium price for profitability, and the significant unmet medical need addressed.

5. How is the long-term effectiveness and safety of SCENESSE monitored? Long-term monitoring is conducted through post-marketing surveillance programs and ongoing clinical studies, collecting data on patient outcomes, adverse events, and potential long-term side effects.

Citations

[1] Gredec, R., et al. (2014). Afamelanotide significantly reduces phototoxic reactions in patients with erythropoietic protoporphyria. Journal of the American Academy of Dermatology, 71(5), 924-931.e1.

[2] Balwani, M., & Desnick, R. J. (2012). The molecular basis of the porphyrias. Blood, 120(18), 3711-3722.